Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2679802 | 1.00 | POLB (0.42) | POLBL3MBTL1DPP4PREPFAP | |
| SCHEMBL1596883 | 1.00 | POLB (0.42) | POLBL3MBTL1DPP4PREPFAP | |
| Hydrochloric Acid SCHEMBL20570928 | 0.98 | POLB (0.41) | POLBL3MBTL1DPP4PREPFAP | |
| SCHEMBL1597059 | 0.94 | POLB (0.48) | POLBL3MBTL1DPP4PREPFAP | |
| SCHEMBL1597060 | 0.94 | POLB (0.48) | POLBL3MBTL1DPP4PREPFAP | |
| SCHEMBL3335647 | 0.94 | POLB (0.48) | POLBL3MBTL1DPP4PREPFAP | |
| Hydrochloric Acid SCHEMBL11895384 | 0.92 | POLB (0.47) | POLBL3MBTL1DPP4PREPFAP | |
| Hydrochloric Acid SCHEMBL11896218 | 0.92 | POLB (0.47) | POLBL3MBTL1DPP4PREPFAP | |
| Tert-Butanol SCHEMBL28911378 | 0.91 | HTT (0.38) | POLBL3MBTL1DPP4NPC1RAB9A | |
| Tert-Butanol SCHEMBL28547075 | 0.85 | POLB (0.42) | POLBL3MBTL1DPP4PREPFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393918-A1 | SELF DEGRADATION-TYPE CDK9 INHIBITOR PRODRUG AND LIPOSOME ENCAPSULATING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-07-03 | — | — | EP | disclosed |
| EP-4364804-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | Janssen Pharmaceutica NV (BE) | 2024-05-08 | — | — | EP | disclosed |
| US-11897900-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-13 | — | — | US | disclosed |
| EP-3833662-B1 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-17 | — | — | EP | disclosed |
| EP-3389654-B1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-115894447-A | METTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-110691784-B | Compounds for inhibiting MCL-1 protein | 美国安进公司 | 2023-03-31 | — | — | CN | disclosed |
| WO-2021158516-A1 | IRE1α MODULATORS AND USES THEREOF | NIMBUS IASO, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-3833662-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | Janssen Pharmaceutica N.V. (BE) | 2021-06-16 | — | — | EP | disclosed |
| US-11014921-B2 | Therapeutic compounds and methods of use thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-05-25 | — | — | US | disclosed |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-29 | — | — | US | disclosed |
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-08 | — | — | US | disclosed |
| US-7432270-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-10-07 | — | — | US | disclosed |
| EP-1956020-A2 | 1-[2-(heterocyclyl-aminomethyl)-piperidin-1-YL]-1-(2-methyl-5-phenyl-heterocyclyl)-methanone derivatives and related compounds as orexin-1 antagonists for the treatment of obesity | SMITHKLINE BEECHAM PLC (GB) | 2008-08-13 | — | — | EP | disclosed |
| EP-1385845-B1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM PLC (GB) | 2008-01-09 | — | — | EP | disclosed |
| EP-1789413-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006031852-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20040143115-A1 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
| EP-1385845-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM PLC (GB) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002090355-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | POLB 1875/4885L3MBTL1 4838/4885DPP4 3346/4885 |
| US-11897900-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | POLB 2535/4885L3MBTL1 2473/4885DPP4 4374/4885 |
| US-11014921-B2 | Therapeutic compounds and methods of use thereof | CD47, C3AR1, HLA-DRB1 | POLB 4161/4885L3MBTL1 1329/4885DPP4 1758/4885 |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | POLB 1875/4885L3MBTL1 4838/4885DPP4 3346/4885 |
| US-20040143115-A1 | N-aroyl cyclic amines | HCRTR1, HCRTR2, CNR1 | POLB 3607/4885L3MBTL1 3402/4885DPP4 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.